---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000075"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T08:22:55.399455+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine settles Lupin patent litigation; generic INGREZZA entry set for March 1, 2038

## Summary
- Settled with Lupin Limited and Lupin Pharmaceuticals; Lupin may sell generic INGREZZA starting March 1, 2038, or earlier under certain circumstances.
- Prior settlements with Sandoz/Crystal and Teva also allow generic entry on March 1, 2038, subject to earlier launch conditions.
- Remaining patent litigation against another ANDA filer is ongoing with trial scheduled for January 2, 2024.
- Agreement will be submitted to FTC and DOJ as required by law.

## SEC filing metadata
- accession: 0000914475-23-000075
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000075/0000914475-23-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000075/nbix-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000075
- JSON: https://secwatch.observer/filing/0000914475-23-000075.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.